Study identifier:D6702C00009
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects with Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Major depressive disorder
Phase 2
No
AZD6765, Placebo
All
152
Interventional
18 Years - 65 Years
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Oct 2014 by AstraZeneca
AstraZeneca
-
The purpose of this research study is to determine whether AZD6765 has an effect on the patient's depression when taken together with current depression medication. In addition, information will be gathered on how well AZD6765 is tolerated, investigate the levels of AZD6765 and the levels of the current depression medication in the blood. In addition, the research staff will determine if AZD6765 has any mood or calming effects (how you feel).
Location
Location
Hollywood, FL, United States
Location
ATLANTA, GA, United States
Location
AUSTIN, TX, United States
Location
BOCA RATON, FL, United States
Location
DALLAS, TX, United States
Location
EAST STROUDSBURG, PA, United States
Location
GAINSVILLE, FL, United States
Location
HARTFORD, CT, United States
Arms | Assigned Interventions |
---|---|
Experimental: AZD6765 100mg 100 mg intravenous (iv) once per dosing day | Drug: AZD6765 IV once per dosing day, multiple times during the treatment period |
Experimental: AZD6765 150mg 150 mg iv once per dosing day | Drug: AZD6765 IV once per dosing day, multiple times during the treatment period |
Placebo Comparator: Placebo Placebo once per dosing day | Drug: Placebo 0.9% saline IV once per dosing day multiple times during the treatment period |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.